Published in J Exp Med on February 02, 1998
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med (2000) 16.09
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2000) 13.13
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36
Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol (2009) 4.90
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med (1999) 3.85
CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med (2004) 3.57
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol (2005) 3.53
PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med (2003) 3.05
How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity (2009) 2.15
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc Natl Acad Sci U S A (2004) 1.96
Susceptible MHC alleles, not background genes, select an autoimmune T cell reactivity. J Clin Invest (2003) 1.80
CD4+CD28- costimulation-independent T cells in multiple sclerosis. J Clin Invest (2001) 1.74
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest (2015) 1.67
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother (2006) 1.66
The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future. J Autoimmun (2007) 1.55
Imaging inflammation of the pancreatic islets in type 1 diabetes. Proc Natl Acad Sci U S A (2004) 1.51
In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A (1999) 1.48
Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints. J Exp Med (2010) 1.41
Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc Natl Acad Sci U S A (2004) 1.32
Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J Exp Med (1998) 1.32
Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci U S A (2000) 1.31
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help. J Exp Med (1999) 1.18
Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun (2013) 1.18
Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J Exp Med (2011) 1.14
Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer (2014) 1.11
Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. J Autoimmune Dis (2005) 1.10
CD28, CTLA-4 and their ligands: who does what and to whom? Immunology (2000) 1.10
Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest (2006) 1.05
Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant (2011) 1.02
A novel pancreatic β-cell targeting bispecific-antibody (BsAb) can prevent the development of type 1 diabetes in NOD mice. Clin Immunol (2014) 1.01
Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: a possible mechanism for deregulation of T lymphocyte activation. Proc Natl Acad Sci U S A (1999) 1.00
Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med (2012) 1.00
Immunoregulatory pathways controlling progression of autoimmunity in NOD mice. Ann N Y Acad Sci (2008) 0.98
Use of nonobese diabetic mice to understand human type 1 diabetes. Endocrinol Metab Clin North Am (2010) 0.97
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol (2006) 0.97
Expression of CTLA-4 molecule in peripheral blood T lymphocytes from patients with systemic lupus erythematosus. J Clin Immunol (1998) 0.96
An early age-related increase in the frequency of CD4+ Foxp3+ cells in BDC2.5NOD mice. Immunology (2007) 0.96
Early treatment of NOD mice with B7-H4 reduces the incidence of autoimmune diabetes. Diabetes (2011) 0.96
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) (2014) 0.92
Role of stromal-cell derived factor-1 in the development of autoimmune diseases in non-obese diabetic mice. Immunology (2002) 0.90
Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer (2012) 0.89
Altered phenotype and function of dendritic cells in children with type 1 diabetes. Clin Exp Immunol (2005) 0.89
The cellular source and target of IL-21 in K/BxN autoimmune arthritis. J Immunol (2013) 0.89
Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells. Blood (2007) 0.89
B1 cells promote pancreas infiltration by autoreactive T cells. J Immunol (2010) 0.89
Exploiting apoptosis for therapeutic tolerance induction. J Immunol (2013) 0.89
PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J (2015) 0.87
Altered immune regulation in type 1 diabetes. Clin Dev Immunol (2013) 0.85
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. Immunity (2016) 0.84
The soluble form of CTLA-4 from serum of patients with autoimmune diseases regulates T-cell responses. Biomed Res Int (2014) 0.84
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV. Case Rep Oncol Med (2015) 0.83
Impaired function of CTLA-4 in the lungs of patients with chronic beryllium disease contributes to persistent inflammation. J Immunol (2013) 0.83
A role for CD45RBlow CD38+ T cells and costimulatory pathways of T-cell activation in protection of non-obese diabetic (NOD) mice from diabetes. Immunology (1999) 0.82
Costimulation couture: a designer approach to regulating autoimmunity. J Clin Invest (2006) 0.82
Recipient cytotoxic T lymphocyte antigen 4 +49 single-nucleotide polymorphism is not associated with acute rejection after liver transplantation in Chinese population. Int J Med Sci (2013) 0.77
Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study. J Immunother Cancer (2015) 0.77
Suppression of acute graft-versus-host response by TCDD is independent of the CTLA-4-IFN-γ-IDO pathway. Toxicol Sci (2013) 0.77
CTLA-4-Tg/CD-28-KO Mice Exhibit Reduced T Cell Proliferation in vivo Compared to CD-28-KO Mice in a Graft-versus-host Disease Model. Korean J Physiol Pharmacol (2012) 0.75
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. Oncologist (2016) 0.75
Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Hum Vaccin Immunother (2016) 0.75
Escherichia coli Heat-Labile Enterotoxin B Limits T Cells Activation by Promoting Immature Dendritic Cells and Enhancing Regulatory T Cell Function. Front Immunol (2017) 0.75
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 9.80
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
Following a diabetogenic T cell from genesis through pathogenesis. Cell (1993) 6.46
Mice lacking MHC class II molecules. Cell (1991) 6.25
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 6.13
Insulin-dependent diabetes mellitus. Cell (1996) 5.06
CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med (1996) 4.97
Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity (1997) 4.05
T helper cell subsets in insulin-dependent diabetes. Science (1995) 3.92
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med (1992) 3.77
CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol (1996) 3.40
The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet (1996) 3.37
Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol (1992) 3.37
CTLA-4: a negative regulator of autoimmune disease. J Exp Med (1996) 3.25
Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med (1995) 3.18
Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. Science (1990) 3.17
Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J Immunol (1995) 3.06
Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev (1994) 2.80
Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science (1996) 2.56
Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci U S A (1996) 2.53
Co-stimulation in T cell responses. Curr Opin Immunol (1997) 2.35
The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev (1996) 2.18
CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity (1996) 2.09
Is CTLA-4 a master switch for peripheral T cell tolerance? J Immunol (1997) 1.98
Genetic control of diabetes progression. Immunity (1997) 1.95
MHC-linked protection from diabetes dissociated from clonal deletion of T cells. Science (1990) 1.70
Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol (1996) 1.69
Costimulation and autoimmunity. Curr Opin Immunol (1996) 1.13
CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion. J Exp Med (1997) 1.13
In vivo sequence requirements of the SV40 early promotor region. Nature (1981) 25.00
The ovalbumin gene-sequence of putative control regions. Nucleic Acids Res (1980) 18.04
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Ovalbumin gene: evidence for a leader sequence in mRNA and DNA sequences at the exon-intron boundaries. Proc Natl Acad Sci U S A (1978) 14.82
A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature (1998) 10.35
Organisation and sequences at the 5' end of a cloned complete ovalbumin gene. Nature (1979) 9.30
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
Deletions covering the putative promoter region of early mRNAs of simian virus 40 do not abolish T-antigen expression. Proc Natl Acad Sci U S A (1980) 7.77
CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (1992) 7.15
Following a diabetogenic T cell from genesis through pathogenesis. Cell (1993) 6.46
Organ-specific disease provoked by systemic autoimmunity. Cell (1996) 6.44
A multiplicity of CCAAT box-binding proteins. Cell (1987) 6.37
Mice lacking MHC class II molecules. Cell (1991) 6.25
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 6.13
Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J Immunol (1982) 5.92
Empty MHC class I molecules come out in the cold. Nature (1990) 5.53
Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase. Proc Natl Acad Sci U S A (1981) 5.38
From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity (1999) 5.38
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature (2001) 5.32
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 5.30
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol (2001) 5.17
Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science (1999) 4.97
beta-Cell death during progression to diabetes. Nature (2001) 4.61
T helper cell subsets in insulin-dependent diabetes. Science (1995) 3.92
Limited diversity of gamma delta antigen receptor genes of Thy-1+ dendritic epidermal cells. Cell (1988) 3.88
Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med (1999) 3.85
Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. Annu Rev Immunol (1990) 3.68
Induction of altered chromatin structures by simian virus 40 enhancer and promoter elements. Nature (1984) 3.68
The dendritic cell populations of mouse lymph nodes. J Immunol (2001) 3.57
TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol (2001) 3.53
CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol (1999) 3.49
Developmentally ordered appearance of thymocytes expressing different T-cell antigen receptors. Nature (1988) 3.48
Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol (1992) 3.37
Antigen/MHC-specific T cells are preferentially exported from the thymus in the presence of their MHC ligand. Cell (1989) 3.29
Superantigens interact with MHC class II molecules outside of the antigen groove. Cell (1990) 3.20
Structure of transcribing chromatin. Prog Nucleic Acid Res Mol Biol (1980) 3.09
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res (2000) 2.89
Another view of the selective model of thymocyte selection. Cell (1993) 2.85
Several mechanisms can account for defective E alpha gene expression in different mouse haplotypes. Proc Natl Acad Sci U S A (1983) 2.84
Mice lacking all conventional MHC class II genes. Proc Natl Acad Sci U S A (1999) 2.83
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A (1998) 2.78
Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity (1997) 2.72
CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice. J Exp Med (1995) 2.70
Costimulatory regulation of T cell function. Curr Opin Cell Biol (1999) 2.69
Conserved major histocompatibility complex class II boxes--X and Y--are transcriptional control elements and specifically bind nuclear proteins. Proc Natl Acad Sci U S A (1987) 2.55
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A (1997) 2.53
Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci U S A (1996) 2.53
The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8- T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer. J Exp Med (1987) 2.52
Co-evolution from yeast to mouse: cDNA cloning of the two NF-Y (CP-1/CBF) subunits. EMBO J (1990) 2.49
Recognition of self antigens by skin-derived T cells with invariant gamma delta antigen receptors. Science (1991) 2.49
Mice lacking TdT: mature animals with an immature lymphocyte repertoire. Science (1993) 2.42
Targeted complementation of MHC class II deficiency by intrathymic delivery of recombinant adenoviruses. Immunity (1997) 2.38
Expression and function of the CD3-antigen receptor on murine CD4+8+ thymocytes. Nature (1987) 2.38
Cassette vectors directing expression of T cell receptor genes in transgenic mice. J Immunol Methods (1995) 2.37
Co-stimulation in T cell responses. Curr Opin Immunol (1997) 2.35
Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell (1996) 2.32
Mice lacking the MHC class II-associated invariant chain. Cell (1993) 2.30
Allorecognition by NK cells: nonself or no self? Immunol Today (1992) 2.21
How much TCR does a T cell need? Immunity (2001) 2.18
The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev (1996) 2.18
Structure, function, and serology of the T-cell antigen receptor complex. Annu Rev Immunol (1987) 2.17
Compartmentalization of MHC class II gene expression in transgenic mice. Cell (1988) 2.08
Prevention of allogeneic bone marrow graft rejection by H-2 transgene in donor mice. Science (1989) 2.08
The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell (1983) 2.04
Regulation of T-cell receptor gamma-chain RNA expression in murine Thy-1+ dendritic epidermal cells. Nature (1987) 2.00
Dominant negative analogs of NF-YA. J Biol Chem (1994) 1.99
Genetic influences on the end-stage effector phase of arthritis. J Exp Med (2001) 1.99
Genetic control of diabetes progression. Immunity (1997) 1.95
CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med (1993) 1.93
A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. Hum Gene Ther (1996) 1.91